The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

2019964 citationsJournal Articlehybrid Open Access

Authors

ClinicalTrials.gov identifier: NCT02107703.

Good health and well-being

Published in: JAMA Oncology

Volume 6, Issue 1, pp. 116-116

Field-Weighted Citation Impact: 78.29